Table 4.
Immunotherapy agent (trial) | # of patients | Primary endpoint | Design | Ref. |
---|---|---|---|---|
Ipilimumab | 600 | OS | Chemotherapy-naive; ipilimumab 10 mg/kg IV or placebo | (148) |
PSA-TRICOM | 1200 | OS | Chemotherapy-naive; vaccine alone or vaccine with adjuvant doses of GM-CSF | (46) |
Ipilimumab | 800 | OS | Post-docetaxel; ipilimumab 10 mg/kg IV or placebo | (149) |